drugset / Trial / NCT06495229
Study of CM310 in Adolescent Subjects With Atopic Dermatis
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
Timeline
- Start
- 2024-08-02
- Primary completion
- 2026-08-30
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | — | — |